Our Antitrust Health Horizons webinar series focuses on how life sciences and healthcare companies should navigate a rapidly evolving HSR landscape—and what to do now as premerger notification requirements continue to shift.
HSR premerger notification requirements remain in flux. While the prior HSR reporting form is currently back in effect, the 2025 Updated Form, its subsequent vacatur and appeal, and the agencies’ recent request for public comments on the effectiveness of the Updated Form all point in the same direction: more upfront disclosure, more need for strategic antitrust advice, and more scrutiny during the HSR period. Whether the 2025 Updated Form returns or a revised version replaces it, companies should expect continued pressure on deal timing, preparation, and internal coordination.